ClinicalTrials.gg
RecruitingNCT06197412Updated Jul 3, 2024

Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer

A Phase 4 interventional study of Yunnan Baiyao in Diabetic Foot Ulcer Treatment, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Peking University Third Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Diabetic Foot with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Diabetic Foot · China.

Planned enrollment
13th of 41
100 · median 70
Started
2023
with 5 others
Phase 4
6 of 52
4 open now
Primary completion
2025-12
later than 8 of 23 live
Registered
35th of 52
by date
Lead sponsor
6 of 52
Peking University Third Hospital

Among the 52 studies in Diabetic Foot with a site in China, this one is the 13th largest by planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2023, is one of 6 in phase 4, reaches primary completion later than 8 of the 23 other live ones, and was the 35th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

21 of the 52 studies in Diabetic Foot with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Diabetic Foot with a site in China, or all of them as a file.
02

Study summary

Yunnan Baiyao has been treating all kinds of wounds for 120 years, but the evidence of Evidence-based medicine that is truly convincing is insufficient, making its best application method unclear. This study explored the possible indications and use methods of Yunnan Baiyao in different stages of Diabetic foot, and obtained Evidence-based medicine evidence of clinical efficacy. Obtain the discarded tissues of Diabetic foot patients in the treatment and control groups of Yunnan Baiyao after wound debridement, conduct Transcriptome (BulkRNA seq) analysis and detection on the wound tissues, and analyze the related signal pathways and functional genes with significant differences, to help clarify the possible treatment targets of Yunnan Baiyao.

03

Conditions studied

  • Diabetic Foot Ulcer Treatment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of the subjects is 18-80 years old;
  2. Diagnose diabetes according to WHO standards;
  3. Diagnosis of Diabetic foot;
  4. Confirmed as one of the stages of infection progression and granulation growth;
  5. Voluntarily participate in this study and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
  2. Blood glucose is out of control, Glucose test#Fasting blood sugar>15mmol /L, >12%;
  3. There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;
  4. Serum albumin\<20g/L; \<60g/L; \<50 × 109/L;
  5. Late stage subjects with malignant tumors;
  6. Active period of diseases;
  7. Have a history of allergy to Yunnan Baiyao;
  8. The subject is unable to cooperate or has mental disorders;
  9. According to the judgment of the researcher, the subject has a clear reason that cannot be removed and affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    control group 1

    The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks

  • Experimental
    powder group 1

    On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks

    Drug: Yunnan Baiyao

  • Experimental
    ointment group 1

    On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks

    Drug: Yunnan Baiyao

  • No intervention
    control group 2

    The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks

  • Experimental
    powder group 2

    On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks

    Drug: Yunnan Baiyao

  • Experimental
    ointment group 2

    On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks

    Drug: Yunnan Baiyao

Interventions

  • On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

06

What researchers measure

Primary outcomes

  1. 2-week reduction rate of wound area

    Difference in wound area before and after treatment

    Time frame: 2 weeks

Secondary outcomes

  1. 2-week cure rate of wound

    Proportion of healed wounds to total number of cases

    Time frame: 2 weeks

  2. Local infection situation

    No infection; local infection reduction; Local infection maintained;Local infection aggravated; Disseminated infection

    Time frame: 2 weeks

  3. Granulation tissue health status

    Healthy granulation, inflammatory granulation, infected granulation, edema granulation, aging granulation

    Time frame: 2 weeks

  4. Pain scoring

    visual analogue scale

    Time frame: 2 weeks

  5. Microcirculation examination

    ankle brachial index, ABI

    Time frame: 2 weeks

  6. Minor amputation rate

    distal ankle amputation

    Time frame: 3 weeks

  7. Major amputation rate

    leg and thigh amputations

    Time frame: 3 weeks

  8. Mortality

    the proportion of dead subjects to total subjects

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 21 phase 4 interventional studies under Diabetic Foot, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2023
First posted
Jan 9, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06197412
Responsible party
Long Zhang (Professor, Peking University Third Hospital) — Principal investigator
First posted
Jan 9, 2024
Start date
Dec 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Jul 3, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yunnan baiyao

Start the discussion